Skip to main content
Smart Investors Daily
QT

OTC · QTXB

QuantRx Biomedical Corporation

Healthcare · Medical - Instruments & Supplies

$0.00

Up+$0.00 (+400.00%)

Updated Aug 25, 2026, 8:47 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
118.05K
P/E ratio
-0.08
Dividend yield
0.00%
52-week range
— – —
Volume
22.1K
Avg. volume
24.98K

Price performance

QTXB price history

1M range · 0 trading sessions · Daily adjusted prices

QTXB does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest QTXB news

The latest Smart Investors Daily articles mentioning QTXB.

QTXB research

Overview

Company profile and research snapshot.

Company profile

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.